Parkinson's disease

PD · Neurology · 4 drugs · 2 indications

Neurodegenerative movement disorder.
Competitive Landscape (4 drugs)
DrugCompanyMechanismModalityRouteStage
TavapadonABBVD3/D2 partial agonistSmall moleculePOFILED
PrasinezumabROG.SWAlpha-synuclein targetingAntibodyIVPHASE3
GlovadalenUCBDopamine D1 receptor PAMSmall moleculeOralPHASE2
NeuproUCBDopamine agonistSmall moleculeTransdermalAPPROVED
Indications (2)
Parkinson's disease
Prasinezumab PHASE2Glovadalen PHASE2Neupro APPROVEDTavapadon FILED
Early Parkinson's disease
Upcoming Catalysts
Tavapadon - Parkinson's - FDA ApprovalREGULATORY
ABBVQ3 2026
Prasinezumab - Parkinson's - Ph2b - Topline (PADOVA)CLINICAL
ROG.SW2027
Data from Supabase · Updated 2026-03-24